TickerFacts.

Repligen Corp (RGEN): Operating Cash Flow

Annual figures by period end, from SEC filings.

$117.42M
Year ended 2025-12-31
$134.86M
Trailing 12 months to 2026-06-30
-12.0%
3-year compound annual growth
+13.4%
5-year compound annual growth
$175.39M2010-03-31: -$2.45M2011-03-31: $3.23M2012-12-31: $13.44M2013-12-31: $25.93M2016-12-31: $7.52M2017-12-31: $17.45M2018-12-31: $32.77M2019-12-31: $67.22M2020-12-31: $62.62M2021-12-31: $119.02M2022-12-31: $172.08M2023-12-31: $113.92M2024-12-31: $175.39M2025-12-31: $117.42M$117.42M
2010-03-31 Operating Cash Flow (USD) 2025-12-31
Period endedOperating Cash FlowChange YoYSource filing
2025-12-31$117.42M-33.1%2026-02-26, From 2025-01-01
2024-12-31$175.39M+54.0%2026-02-26, From 2024-01-01
2023-12-31$113.92M-33.8%2026-02-26, From 2023-01-01
2022-12-31$172.08M+44.6%2025-03-14, From 2022-01-01
2021-12-31$119.02M+90.0%2024-11-18, From 2021-01-01
2020-12-31$62.62M-6.8%2023-02-22, From 2020-01-01
2019-12-31$67.22M+105.1%2022-02-17, From 2019-01-01
2018-12-31$32.77M+87.8%2021-02-24, From 2018-01-01
2017-12-31$17.45M+132.0%2020-02-26, From 2017-01-01
2016-12-31$7.52Mn/a2019-03-01, From 2016-01-01
No annual figure between 2013-12-31 and 2016-12-31.
2013-12-31$25.93M+92.9%2014-03-14, From 2013-01-01
2012-12-31$13.44Mn/a2014-03-14, From 2012-01-01
No annual figure between 2011-03-31 and 2012-12-31.
2011-03-31$3.23Mn/m2013-03-15, From 2010-04-01
2010-03-31-$2.45Mn/a2012-03-15, From 2009-04-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedOperating Cash FlowChange YoY
Repligen Corp (RGEN)2025-12-31$117.42M-33.1%
BioCryst Pharmaceuticals Inc (BCRX)2025-12-31$347.37Mn/m
ADMA Biologics, Inc. (ADMA)2025-12-31$50.40M-57.5%
Novavax Inc (NVAX)2025-12-31-$244.63Mn/m
Tarsus Pharmaceuticals, Inc. (TARS)2025-12-31-$12.45Mn/m
Bio-Techne Corp (TECH)2026-06-30$292.07M+1.6%
Immunocore Holdings plc (IMCR)2025-12-31-$10.71Mn/m
Halozyme Therapeutics, Inc. (HALO)2025-12-31$651.56M+36.0%
Krystal Biotech, Inc. (KRYS)2025-12-31$200.87M+62.7%

Compare RGEN, BCRX, ADMA, NVAX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗